Clinical trial
A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease
NCT05424276 is registered in ClinicalTrials.gov with ABLi Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease
- Lead sponsor
- ABLi Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 15, 2023
- Completion date
- September 13, 2025
- Enrollment
- 137 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.